For the month ended 31 August 2026, JW Therapeutics (HKEX: 02126) reported a minor expansion of its share base, driven exclusively by employee option exercises.

Key Points

1. Share Capital Structure • Authorised capital remained unchanged at 5.00 billion ordinary shares with an aggregate par value of USD 50,000. • Total issued shares (excluding treasury shares) rose by 38,940 to 416.77 million. The company continues to hold no treasury shares.

2. Source of Share Increase • All new shares were generated through the exercise of Pre-IPO Incentivization Scheme options granted on 30 June 2020 at an exercise price of USD 0.0001 per share. • Cash proceeds from these exercises totalled USD 3.89.

3. Outstanding Equity Incentives • Post-transaction, 22.73 million share options remain outstanding across the company’s Pre-IPO and Post-IPO schemes. • The Post-IPO scheme still has capacity for a further 3.67 million option grants. • The 2019 Restricted Share Unit Scheme retains authority to issue up to 1.20 million shares; no RSUs were vested or transferred during the month.

4. Public Float • JW Therapeutics confirmed compliance with the Main Board’s minimum 25% public-float requirement as at 31 August 2026.

No warrants, convertible securities or other share-issuing arrangements were active during the period, and there were no share repurchases or treasury-share movements reported.